Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of 54%, an expansion of 1,900 bps and 900 bps, respectively, versus prior yearFull Year 2025 Adjusted EBITDA of $205.0 million, compares favorably to $183.1 million in 2024 GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results f
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent BioSolutions Announces New $50 Million Stock Repurchase Program [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces New $50 Million Stock Repurchase ProgramGlobeNewswire
- Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health PreparednessGlobeNewswire
- Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray MultipacksGlobeNewswire
- Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 2/26/26 - Form 8-K
- 2/10/26 - Form 4
- 2/10/26 - Form 4
- EBS's page on the SEC website